ArticlePharmacology, biochemistry, and behavior2009
Using prepulse inhibition to detect functional D3 receptor antagonism: effects of WC10 and WC44.
Article in Pharmacology, biochemistry, and behavior, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 16 citations in OpenAlex.
- Dopamine D3 receptor: A neglected participant in Parkinson Disease pathogenesis and treatment?Ageing research reviews · 2020Review
- Dopamine D3 Receptor Antagonists as Potential Therapeutics for the Treatment of Neurological Diseases.Frontiers in neuroscience · 2016Review
- Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis.Journal of medicinal chemistry · 2015Article
- Dopamine D3 and 5-HT1B receptor dysregulation as a result of psychostimulant intake and forced abstinence: Implications for medications development.Neuropharmacology · 2014Review
- Fos expression in response to dopamine D3-preferring phenylpiperazine drugs given with and without cocaine.Synapse (New York, N.Y.) · 2013Article
- Synthesis andMedChemComm · 2013Article
- Comparison of the binding and functional properties of two structurally different D2 dopamine receptor subtype selective compounds.ACS chemical neuroscience · 2012Article
- Phenylpiperazine derivatives with selectivity for dopamine D3 receptors modulate cocaine self-administration in rats.Neuropharmacology · 2012Article
- Stereochemical and neuroanatomical selectivity of pramipexole effects on sensorimotor gating in rats.Brain research · 2012Article
- Disparate effects of pramipexole on locomotor activity and sensorimotor gating in Sprague-Dawley rats.Pharmacology, biochemistry, and behavior · 2011Article
- Effect of cyclosporin A on the uptake of D3-selective PET radiotracers in rat brain.Nuclear medicine and biology · 2011Article
- Parametric approaches towards understanding the effects of the preferential D3 receptor agonist pramipexole on prepulse inhibition in rats.Pharmacology, biochemistry, and behavior · 2010Article
- The effects of the dopamine D2 agonist sumanirole on prepulse inhibition in rats.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2010Article
- The effects of pramipexole on prepulse inhibition and locomotor activity in C57BL/6J mice.Behavioural pharmacology · 2010Article
- Pramipexole effects on startle gating in rats and normal men.Psychopharmacology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Prepulse inhibition of startle (PPI) is an operational measure of sensorimotor gating that is impaired in schizophrenia. Treatment with mixed dopamine D2/D3 antagonists diminishes schizophrenia symptoms, and opposes dopamine agonist-induced PPI deficits in rats. There are reasons to believe that functional D3 receptor antagonists might offer more favorable therapeutic profiles compared to current antipsychotics. However, D3-related drug discovery is hampered by the absence of assays sensitive to D3-mediated (antipsychotic) properties in vivo. Here, we characterized two putative D3-active compounds - WC10 and WC44 - in a PPI-based screening assay, comparing the sensitivity of test compounds to oppose PPI deficits induced by the mixed D1/D2-like agonist apomorphine vs. the preferential D3 agonist pramipexole in rats. WC10, WC44 (0, 1, 3, 10 mg/kg, each), and the preferential D2 antagonist L741,626 (0, 1 mg/kg) were studied, in combination with apomorphine (0, 0.5 mg/kg), or pramipexole (0, 1 mg/kg). L741,626 prevented apomorphine-, but not pramipexole-induced PPI deficits. WC10, but not WC44, prevented apomorphine-induced PPI deficits; both compounds opposed pramipexole-induced PPI deficits, suggesting functional D3 and D1/D2 antagonist profiles for WC10, and functional D3 receptor antagonism for WC44. This assay may be valuable for detecting predominantly D3 vs. D2 receptor-linked mechanisms of action in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.